• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Many Health Insurance Companies Are Being Overcharged for Some Radiology Services

Article

Patients and providers are having to pay more toward their health plans due to these common radiology services charging more than needed.

Health insurance companies are overpaying for some common radiology services, leading to higher costs for patients and providers, according information shared from a study by Michigan State University (MSU).

Published in the journal Radiology, researchers found that the maximum negotiated price for shoppable radiology services, on average, was 3.8 times the minimum negotiated price in the same hospital among various insurance companies and 1.2 times the minimum negotiated price in the same hospital among the same insurance company’s multiple health plans.

“Many commercial plans are leaving money on the table when negotiating prices with hospitals, especially for expensive CT and MRI scans,” said study co-author Ge Bai, a former doctoral student in MSU's Eli Broad College of Business and current professor of accounting, and health policy and management at Johns Hopkins University, in a release. “High prices paid by commercial plans eventually come back to bite patients and providers through high premiums and out-of-pocket costs.” 

The study found that the multiple insurance plans in contract with hospitals negotiated different prices for the same services within the same hospital, and even negotiated different prices across their own various health plans.

Researchers studied commercial negotiated prices from private payers for the 13 radiology services. Services that require high-cost equipment like a CT scanner and MRI, had more wide cost variations and higher prices relative to Medicare when compared to other radiology services, according to the information shared.

Out of the reviewed services, brain CT scans had the greatest price gap, in which 25% of hospital-insurance company pairs had set their maximum negotiated price at more than 2.4 times their minumum price.

Bai said, because of the Price Transparency Rule disclosing U.S. hospital pricing information, it "took the blindfold off the eyes of commercial payers, forcing them to recognize the fact that they are often paying too much."

“Equipped with pricing information, radiologists can change the landscape of care delivery to benefit patients and payers.”

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.